Addressing Diagnostics Delay in Multiple Myeloma: Insights from a National Survey of Primary Care Providers
The Journal of Applied Laboratory Medicine · 04.11.2026 · 11 (6) · 1478-1490
DOI: 10.1093/jalm/jfag087 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 09.06.2026. Verfasst von Bhrugu Yagnik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Affairs, The Binding Site Inc., part of Thermo Fisher Scientific, San Diego, CA, United States. Hauptthemen laut MEDLINE: Multiple Myeloma, Delayed Diagnosis, Physicians, Primary Care, Practice Patterns, Physicians'. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Binding Site Inc., part of Thermo Fisher Scientific, Bioinformatics, LLC.
Abstract (Originalsprache)
Background
Our aim was to assess the knowledge, awareness, and confidence of US primary care providers (PCPs) in assessing multiple myeloma (MM) and related plasma cell disorders.
Methods
A survey with quantitative and qualitative questions was conducted from October to December 2024. A total of 560 respondents met the criteria of a representative US PCP cohort, but only 300 respondents were invited to continue the rest of the survey. These respondents had ordered serum protein electrophoresis (SPEP) in the past 12 months and believed that SPEP should be ordered for plasma cell disorder diagnosis.
Results
Nearly half of the representative US PCP cohort (46%) do not order tests for plasma cell disorders. Among the 300 who do, there is generally good awareness of symptoms and high-risk characteristics, but only 28% follow guideline-recommended paired testing of SPEP and serum free light chains. The majority (80%) lack confidence in appropriate test selection and interpretation, often relying on peers and hematologists for guidance. Additionally, only 15% of the US PCPs have access to and use myeloma diagnostic ordering sets and panels, while 54% express interest in utilizing such tools. The PCPs identified barriers like insufficient education, collaboration, and specialist support to patient care and outcomes.
Conclusions
The study reveals significant gaps in the understanding and practice of MM diagnostic testing in primary care. Results indicate insufficient knowledge and inadequate utilization of testing guidelines, including low confidence in test ordering and interpretation. The survey suggests a lack of comprehensive, guideline-adherent MM diagnostic panels offered by US laboratories.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Scientific Affairs, The Binding Site Inc., part of Thermo Fisher Scientific, San Diego, CA, United States.
- Department of Family and Community Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States.
- Clinical Genomics and Therapeutics Division, Translational Genomics Research Institute (TGen), City of Hope Cancer Center, Phoenix, AZ, United States.
- International Myeloma Foundation, Studio City, CA, United States.
ORCID-Profile: Bhrugu Yagnik
Förderung
- The Binding Site Inc., part of Thermo Fisher Scientific
- Bioinformatics, LLC
Zitieren
APA
Yagnik, B., Pauli, J., Watson, B., & Mikhael, J. (2026). Addressing Diagnostics Delay in Multiple Myeloma: Insights from a National Survey of Primary Care Providers. The Journal of Applied Laboratory Medicine, 11(6), 1478-1490. https://doi.org/10.1093/jalm/jfag087
Vancouver
Yagnik B, Pauli J, Watson B, Mikhael J. Addressing Diagnostics Delay in Multiple Myeloma: Insights from a National Survey of Primary Care Providers. The Journal of Applied Laboratory Medicine. 2026;11(6):1478-1490. doi:10.1093/jalm/jfag087
BibTeX
@article{Yagnik2026,
author = {Yagnik, Bhrugu and Pauli, Jill and Watson, Brittany and Mikhael, Joseph},
title = {Addressing Diagnostics Delay in Multiple Myeloma: Insights from a National Survey of Primary Care Providers},
journal = {The Journal of Applied Laboratory Medicine},
year = {2026},
volume = {11},
number = {6},
pages = {1478--1490},
doi = {10.1093/jalm/jfag087}
}
EUVIMED